Skip to main content
Top
Published in: Current Bladder Dysfunction Reports 2/2019

Open Access 01-06-2019 | Neurogenic Bladder | Pediatric Bladder Dysfunction (J Thomas and D Clayton, Section Editors)

The Current Role of Botox in a Pediatric Neurogenic Bladder Condition

Author: Paweł Kroll

Published in: Current Bladder Dysfunction Reports | Issue 2/2019

Login to get access

Abstract

Purpose of Review

The neurogenic bladder is a medical term that describes a variety of bladder and sphincter dysfunctions. There are two major dangerous functional problems in a child with neurogenic bladder: high intravesical pressure in the storage phase and high pressure during urination. Two basic goals for urologic treatment in those children are protection of urinary tract from complications and improvement of continence in older children. This review focuses on the current role of botulinum toxin treatment in children with neurogenic bladder.

Recent Findings

At the beginning, treatment in this group of children is conservative. Oral anticholinergic therapy is aimed at decreasing bladder pressures during the storage phase. Clean intermittent catheterization enables bladder emptying if voiding is insufficient. Nevertheless, in a number of children such an approach fails, in some patients, troublesome side effects occur. In cases when standard therapy provides no improvement or if complications develop on the proper conservative treatment, surgical procedures are suggested. Operations are aimed at the surgical enlargement of bladder capacity. There are some reports on the efficacy of cystoscopic detrusor botulinum toxin injections in the treatment of neurogenic bladder in children.

Summary

Cystoscopic administration of botulinum toxin represents an alternative method of treatment to surgery for children with neurogenic bladder and could be considered an alternative to oral anticholinergic therapy.
Literature
3.
go back to reference Kroll P, Zachwieja J. Complications of untreated and ineffectively treated neurogenic bladder dysfunctions in children: our own practical classification. Eur Rev Med Pharmacol Sci. 2016;20:1229–37.PubMed Kroll P, Zachwieja J. Complications of untreated and ineffectively treated neurogenic bladder dysfunctions in children: our own practical classification. Eur Rev Med Pharmacol Sci. 2016;20:1229–37.PubMed
4.
go back to reference Marshall DF, Boston VE. Does bladder capacity assessment by frequency/volume chart correlate well with urodynamic estimation in children with spina bifida? Eur J Pediatr Surg. 2001;11(Suppl 1):S24–7.CrossRefPubMed Marshall DF, Boston VE. Does bladder capacity assessment by frequency/volume chart correlate well with urodynamic estimation in children with spina bifida? Eur J Pediatr Surg. 2001;11(Suppl 1):S24–7.CrossRefPubMed
5.
go back to reference Hjälmås K. Urodynamics in normal infants and children. Scand J Urol Nephrol Suppl. 1988;114:20–7.PubMed Hjälmås K. Urodynamics in normal infants and children. Scand J Urol Nephrol Suppl. 1988;114:20–7.PubMed
6.
go back to reference Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the Standardization Committee of the International Children’s Continence Society. Neurourol Urodynam. 2016;35:471–81.CrossRef Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the Standardization Committee of the International Children’s Continence Society. Neurourol Urodynam. 2016;35:471–81.CrossRef
7.
go back to reference Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia. 1990;28:217–29.PubMed Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia. 1990;28:217–29.PubMed
8.
go back to reference Snow-Lisy DC, Yerkes EB, Cheng EY. Update on urological management of spina bifida from prenatal diagnosis to adulthood. J Urol. 2015;194:288–96.CrossRefPubMed Snow-Lisy DC, Yerkes EB, Cheng EY. Update on urological management of spina bifida from prenatal diagnosis to adulthood. J Urol. 2015;194:288–96.CrossRefPubMed
10.
go back to reference McGuire EJ, Woodside JR, Bordin TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;136:205–9.CrossRef McGuire EJ, Woodside JR, Bordin TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;136:205–9.CrossRef
11.
go back to reference Bauer SB, Hallet M, Khoshbin S, Lebowitz RL, Winston KR, Gibson S, et al. Predective value of urodynamic evaluation in newborns with myelodysplasia. JAMA. 1984;252:650–65.CrossRefPubMed Bauer SB, Hallet M, Khoshbin S, Lebowitz RL, Winston KR, Gibson S, et al. Predective value of urodynamic evaluation in newborns with myelodysplasia. JAMA. 1984;252:650–65.CrossRefPubMed
12.
go back to reference Stein R, Assion C, Beetz R, Bürst M, Cremer R, Ermert A, et al. Neurogene Blasenfunktions-störungen bei Patienten mit Meningomyelozele. Urologe A. 2015;54:239–53.CrossRefPubMed Stein R, Assion C, Beetz R, Bürst M, Cremer R, Ermert A, et al. Neurogene Blasenfunktions-störungen bei Patienten mit Meningomyelozele. Urologe A. 2015;54:239–53.CrossRefPubMed
13.
go back to reference Gerridzen RG, Thijssen AM, Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J Urol. 1992;147:416–8.CrossRefPubMed Gerridzen RG, Thijssen AM, Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J Urol. 1992;147:416–8.CrossRefPubMed
14.
go back to reference Mourtzinos A, Stoffel JT. Management goals for the spina bifida neurogenic bladder: a review from infancy to adulthood. Urol Clin North Am. 2010;37:527–35.CrossRefPubMed Mourtzinos A, Stoffel JT. Management goals for the spina bifida neurogenic bladder: a review from infancy to adulthood. Urol Clin North Am. 2010;37:527–35.CrossRefPubMed
15.
go back to reference Baek M, Kang JY, Jeong J, Kim DK, Kim KM. Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia. Int Urol Nephrol. 2013;45:703–9.CrossRefPubMed Baek M, Kang JY, Jeong J, Kim DK, Kim KM. Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia. Int Urol Nephrol. 2013;45:703–9.CrossRefPubMed
16.
go back to reference Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972;107:458–61.CrossRefPubMed Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972;107:458–61.CrossRefPubMed
17.
go back to reference Krane RJ, Olsson CA. Phenoxybenzamine in neurogenic bladder dysfunction. I. A theory of micturition. J Urol. 1973;110:650–2.CrossRefPubMed Krane RJ, Olsson CA. Phenoxybenzamine in neurogenic bladder dysfunction. I. A theory of micturition. J Urol. 1973;110:650–2.CrossRefPubMed
18.
go back to reference Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Tojo M. The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy. BJU Int. 2000;85:249–53.CrossRefPubMed Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Tojo M. The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy. BJU Int. 2000;85:249–53.CrossRefPubMed
19.
go back to reference de Voogt HJ, van der Sluis C. Preliminary evaluation of alpha-adrenergic blocking agents in children with neurogenic bladder due to myelomeningocele. Dev Med Child Neurol Suppl. 1976;37:82–8. de Voogt HJ, van der Sluis C. Preliminary evaluation of alpha-adrenergic blocking agents in children with neurogenic bladder due to myelomeningocele. Dev Med Child Neurol Suppl. 1976;37:82–8.
20.
go back to reference Schulte-Baukloh H, Michael T, Miller K, Knispel HH. Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. BJU Int. 2002;90:716–20.CrossRefPubMed Schulte-Baukloh H, Michael T, Miller K, Knispel HH. Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. BJU Int. 2002;90:716–20.CrossRefPubMed
21.
go back to reference Homsy Y, Arnold P, Zhang W. Phase IIb/III dose ranging study of tamsulosin as treatment for children with neuropathic bladder. J Urol. 2011;186:2033–9.CrossRefPubMed Homsy Y, Arnold P, Zhang W. Phase IIb/III dose ranging study of tamsulosin as treatment for children with neuropathic bladder. J Urol. 2011;186:2033–9.CrossRefPubMed
22.
go back to reference Kroll P, Gajewska E, Zachwieja J, Sobieska M, Makowski P. An evaluation of the efficacy of selective alpha-blockers in the treatment of children with neurogenic bladder dysfunction--preliminary findings. Int J Environ Res Public Health. 2016;15,13(3) Kroll P, Gajewska E, Zachwieja J, Sobieska M, Makowski P. An evaluation of the efficacy of selective alpha-blockers in the treatment of children with neurogenic bladder dysfunction--preliminary findings. Int J Environ Res Public Health. 2016;15,13(3)
23.
go back to reference Austin PF, Homsy YL, Masel JL, Cain MP, Casale AJ, Rink RC. Alpha-adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. J Urol. 1999;162:1064–7.CrossRefPubMed Austin PF, Homsy YL, Masel JL, Cain MP, Casale AJ, Rink RC. Alpha-adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. J Urol. 1999;162:1064–7.CrossRefPubMed
24.
go back to reference Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98:503–7.CrossRefPubMed Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98:503–7.CrossRefPubMed
25.
go back to reference Blais AS, Bergeron M, Nadeau G, Ramsay S, Bolduc S. Anticholinergic use in children: persistence and patterns of therapy. Can Urol Assoc J. 2016;10:137–40.CrossRefPubMedPubMedCentral Blais AS, Bergeron M, Nadeau G, Ramsay S, Bolduc S. Anticholinergic use in children: persistence and patterns of therapy. Can Urol Assoc J. 2016;10:137–40.CrossRefPubMedPubMedCentral
26.
go back to reference Park SJ, Pai KS, Kim JM, Park K, Kim KS, Song SH, et al. Korean children's continence and enuresis society. Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study. J Korean Med Sci. 2014;29:1550–4.CrossRefPubMedPubMedCentral Park SJ, Pai KS, Kim JM, Park K, Kim KS, Song SH, et al. Korean children's continence and enuresis society. Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study. J Korean Med Sci. 2014;29:1550–4.CrossRefPubMedPubMedCentral
27.
go back to reference Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;4:CD003781. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;4:CD003781.
28.
go back to reference Bolduc S, Moore K, Nadeau G, Lebel S, Lamontage P, Hamel M. Prospective open label study of solifenacin for overactive bladder in children. J Urol. 2010;184:1668–73.CrossRefPubMed Bolduc S, Moore K, Nadeau G, Lebel S, Lamontage P, Hamel M. Prospective open label study of solifenacin for overactive bladder in children. J Urol. 2010;184:1668–73.CrossRefPubMed
29.
go back to reference Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Prospective pilot study of Mirabegron in pediatric patients with overactive bladder. Eur Urol. 2016;70:9–13.CrossRefPubMed Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Prospective pilot study of Mirabegron in pediatric patients with overactive bladder. Eur Urol. 2016;70:9–13.CrossRefPubMed
30.
go back to reference Morin F, Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Dual therapy for refractory overactive bladder in children: a prospective open-label study. J Urol. 2016 Nov 30 Morin F, Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Dual therapy for refractory overactive bladder in children: a prospective open-label study. J Urol. 2016 Nov 30
31.
go back to reference Lee B, Featherstone N, Nagappan P, McCarthy L, O'Toole S. British Association of Paediatric Urologists consensus statement on the management of the neuropathic bladder. J Pediatr Urol. 2016;12:76–87.CrossRefPubMed Lee B, Featherstone N, Nagappan P, McCarthy L, O'Toole S. British Association of Paediatric Urologists consensus statement on the management of the neuropathic bladder. J Pediatr Urol. 2016;12:76–87.CrossRefPubMed
32.••
go back to reference Hascoet J, Peyronnet B, Forin V, Baron M, Capon G, Prudhomme T, et al. Intradetrusor injections of botulinum toxin type a in children with spina bifida: a multicenter study. Urology. 2018;116:161–7. A multicenter trial on 53 children in mean age of 8.5 years showed clinical improvement in 66% patients. Hascoet J, Peyronnet B, Forin V, Baron M, Capon G, Prudhomme T, et al. Intradetrusor injections of botulinum toxin type a in children with spina bifida: a multicenter study. Urology. 2018;116:161–7. A multicenter trial on 53 children in mean age of 8.5 years showed clinical improvement in 66% patients.
33.
go back to reference Khan MK, VanderBrink B A , DeFoor WR, Minevich E, Jackson E, Noh P et al. Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder. J Pediatr Urol. 2016; 12: 104.e1–6. Khan MK, VanderBrink B A , DeFoor WR, Minevich E, Jackson E, Noh P et al. Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder. J Pediatr Urol. 2016; 12: 104.e1–6.
34.
go back to reference Kask M, Rintala R, Taskinen S. Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder. J Pediatr Urol. 2014;10:280–3.CrossRefPubMed Kask M, Rintala R, Taskinen S. Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder. J Pediatr Urol. 2014;10:280–3.CrossRefPubMed
35.
go back to reference Schulte-Baukloh H, Michael T, Stürzebecher B, Knispel HH. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. 2003;44:139–43.CrossRefPubMed Schulte-Baukloh H, Michael T, Stürzebecher B, Knispel HH. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. 2003;44:139–43.CrossRefPubMed
36.
go back to reference Krebs J, Bartel P, Pannek J. Functional outcome of supratrigonal cystectomy and augmentation ileocystoplasty in adult patients with refractory neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2016;35:260–6.CrossRefPubMed Krebs J, Bartel P, Pannek J. Functional outcome of supratrigonal cystectomy and augmentation ileocystoplasty in adult patients with refractory neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2016;35:260–6.CrossRefPubMed
37.
go back to reference Gu HY, Song JK, Zhang WJ, Xie J, Yao QS, Zeng WJ, et al. A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages. Oncotarget. 2017;8:90338–50.PubMedPubMedCentral Gu HY, Song JK, Zhang WJ, Xie J, Yao QS, Zeng WJ, et al. A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages. Oncotarget. 2017;8:90338–50.PubMedPubMedCentral
38.••
go back to reference Sekerci CA, Tanidir Y, Garayev A, Akbal C, Tarcan T, Simsek F. Clinical and urodynamic results of repeated intradetrusor onabotulinum toxin A injections in refractory neurogenic detrusor overactivity: up to 5 injections in a cohort of children with myelodysplasia. Urology. 2018;111:168–75. A study showing that repeated injections of BTX-A are a safe and effective treatment modality in children with NB. Sekerci CA, Tanidir Y, Garayev A, Akbal C, Tarcan T, Simsek F. Clinical and urodynamic results of repeated intradetrusor onabotulinum toxin A injections in refractory neurogenic detrusor overactivity: up to 5 injections in a cohort of children with myelodysplasia. Urology. 2018;111:168–75. A study showing that repeated injections of BTX-A are a safe and effective treatment modality in children with NB.
39.
go back to reference Do Ngoc Thanh C, Audry G, Forin V. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases. J Pediatr Urol. 2009;5:430–6.CrossRefPubMed Do Ngoc Thanh C, Audry G, Forin V. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases. J Pediatr Urol. 2009;5:430–6.CrossRefPubMed
40.
41.
go back to reference Morrisroe SN, O'Connor RC, Nanigian DK, Kurzrock EA, Stone AR. Vesicostomy revisited: the best treatment for the hostile bladder in myelodysplastic children? BJU. 2005;97:397–400.CrossRef Morrisroe SN, O'Connor RC, Nanigian DK, Kurzrock EA, Stone AR. Vesicostomy revisited: the best treatment for the hostile bladder in myelodysplastic children? BJU. 2005;97:397–400.CrossRef
42.
go back to reference González R, Ludwikowski BM. Alternatives to conventional enterocystoplasty in children: a critical review of urodynamic outcomes. Front Pediatr. 2013;1:1–9. González R, Ludwikowski BM. Alternatives to conventional enterocystoplasty in children: a critical review of urodynamic outcomes. Front Pediatr. 2013;1:1–9.
43.
go back to reference Behr-Roussel D, Oger S, Pignol B, Pham E, Le Maux A, Chabrier PE et.al: Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity. Eur Urol 2012; 61: 1054–1061. Behr-Roussel D, Oger S, Pignol B, Pham E, Le Maux A, Chabrier PE et.al: Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity. Eur Urol 2012; 61: 1054–1061.
44.
go back to reference Gormley EA, Lightner DJ, Faraday M, Vasavada SP. American urological association; Society of Urodynamics, female pelvic medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193:1572–80.CrossRefPubMed Gormley EA, Lightner DJ, Faraday M, Vasavada SP. American urological association; Society of Urodynamics, female pelvic medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193:1572–80.CrossRefPubMed
45.
go back to reference Lucas MG, Bosch RJ, Burkhard FC, Cruz F, Madden TB, Nambiar AK, et al. European Association of Urology. EAU guidelines on surgical treatment of urinary incontinence. Eur Urol. 2012;62:1118–29.CrossRefPubMed Lucas MG, Bosch RJ, Burkhard FC, Cruz F, Madden TB, Nambiar AK, et al. European Association of Urology. EAU guidelines on surgical treatment of urinary incontinence. Eur Urol. 2012;62:1118–29.CrossRefPubMed
46.
go back to reference Dolly JO, Lawrence GW. Chapter 3: molecular basis for the therapeutic effectiveness of botulinum neurotoxin type a. Neurourol Urodyn. 2014;33:14–20.CrossRef Dolly JO, Lawrence GW. Chapter 3: molecular basis for the therapeutic effectiveness of botulinum neurotoxin type a. Neurourol Urodyn. 2014;33:14–20.CrossRef
47.
go back to reference Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules. 2010;16:202–20.CrossRefPubMedPubMedCentral Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules. 2010;16:202–20.CrossRefPubMedPubMedCentral
48.
go back to reference Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the protein receptor for botulinum neurotoxin a. Science. 2006;28:592–6.CrossRef Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the protein receptor for botulinum neurotoxin a. Science. 2006;28:592–6.CrossRef
49.
go back to reference Brady C, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin (RTX). Eur Urol. 2004;46:247–53.CrossRefPubMed Brady C, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin (RTX). Eur Urol. 2004;46:247–53.CrossRefPubMed
50.
go back to reference Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174:977–83.CrossRefPubMed Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174:977–83.CrossRefPubMed
51.
go back to reference Top T, Sekerci CA, Isbilen-Basok B, Tanidir Y, Tinay I, Isman FK, et al. The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia. Neurourol Urodyn. 2017;36:1896–902.CrossRefPubMed Top T, Sekerci CA, Isbilen-Basok B, Tanidir Y, Tinay I, Isman FK, et al. The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia. Neurourol Urodyn. 2017;36:1896–902.CrossRefPubMed
52.
go back to reference Schulte-Baukloh H, Priefert J, Knispel HH, Lawrence GW, Miller K, Neuhaus J. Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study. Urology. 2013 May;81(5):1052–7.CrossRefPubMed Schulte-Baukloh H, Priefert J, Knispel HH, Lawrence GW, Miller K, Neuhaus J. Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study. Urology. 2013 May;81(5):1052–7.CrossRefPubMed
53.
go back to reference Hassouna T, Gleason JM, Lorenzo AJ. Botulinum toxin A’s expanding role in the management of pediatric lower urinary tract dysfunction. Curr Urol Rep. 2014;15:426.CrossRefPubMed Hassouna T, Gleason JM, Lorenzo AJ. Botulinum toxin A’s expanding role in the management of pediatric lower urinary tract dysfunction. Curr Urol Rep. 2014;15:426.CrossRefPubMed
54.
go back to reference Gamé X, Mouracade P, Chartier-Kastler E, Viehweger E, Moog R, Amarenco G, et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol. 2009;5(3):156–64.CrossRefPubMed Gamé X, Mouracade P, Chartier-Kastler E, Viehweger E, Moog R, Amarenco G, et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol. 2009;5(3):156–64.CrossRefPubMed
55.
go back to reference Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.CrossRefPubMed Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.CrossRefPubMed
56.
go back to reference Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229–35.CrossRefPubMed Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229–35.CrossRefPubMed
57.
go back to reference Zhou X, Yan HL, Cui YS, Zong HT, Zhang Y: Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl). 2015; 128: 963–8. Zhou X, Yan HL, Cui YS, Zong HT, Zhang Y: Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl). 2015; 128: 963–8.
58.•
go back to reference Zeino M, Becker T, Koen M, Berger C. Riccabona M: Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children. Cent European. J Urol. 2012;65:156–61. This trial showed that BTX injections were efficient even after several injections. Zeino M, Becker T, Koen M, Berger C. Riccabona M: Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children. Cent European. J Urol. 2012;65:156–61. This trial showed that BTX injections were efficient even after several injections.
59.
go back to reference Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L, et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol. 2004;171:845–8. discussion 848.CrossRefPubMed Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L, et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol. 2004;171:845–8. discussion 848.CrossRefPubMed
60.•
go back to reference Šámal V, Mečl J, Šrám J. Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity: pilot single-centre experience and comparison with standard injection into the detrusor. Urol Int. 2013;91:423–8. This trial did not show any significant difference between BTX administration to the submucosa and to the detrusor. Šámal V, Mečl J, Šrám J. Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity: pilot single-centre experience and comparison with standard injection into the detrusor. Urol Int. 2013;91:423–8. This trial did not show any significant difference between BTX administration to the submucosa and to the detrusor.
61.
go back to reference Krhut J, Samal V, Nemec D, Zvara P. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord. 2012;50:904–7.CrossRefPubMed Krhut J, Samal V, Nemec D, Zvara P. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord. 2012;50:904–7.CrossRefPubMed
62.
go back to reference Marte A, Onabotulinumtoxin A. For treating overactive/poor compliant bladders in children and adolescents with neurogenic bladder secondary to myelomeningocele. Toxins (Basel). 2012;28(5):16–24.CrossRef Marte A, Onabotulinumtoxin A. For treating overactive/poor compliant bladders in children and adolescents with neurogenic bladder secondary to myelomeningocele. Toxins (Basel). 2012;28(5):16–24.CrossRef
63.
go back to reference Safari S, Jamali S, Habibollahi P, Arshadi H, Nejat F, Kajbafzadeh AM. Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods. Urology. 2010 Jul;76:225–30.CrossRefPubMed Safari S, Jamali S, Habibollahi P, Arshadi H, Nejat F, Kajbafzadeh AM. Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods. Urology. 2010 Jul;76:225–30.CrossRefPubMed
64.
go back to reference Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30:1242–8.PubMed Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30:1242–8.PubMed
65.•
go back to reference Davis NF, Burke JP, Redmond EJ, Elamin S, Brady CM, Flood HD. Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events. Int Urogynecol J. 2015;26:313–9. In this study no significant differences were found between trigonal and extratrigonal BTX injections. CrossRefPubMed Davis NF, Burke JP, Redmond EJ, Elamin S, Brady CM, Flood HD. Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events. Int Urogynecol J. 2015;26:313–9. In this study no significant differences were found between trigonal and extratrigonal BTX injections. CrossRefPubMed
66.
go back to reference Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184(6):2423–8.CrossRefPubMed Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184(6):2423–8.CrossRefPubMed
67.
go back to reference Ladi-Seyedian SS, Sharifi-Rad L, Kajbafzadeh AM. Intravesical electromotive botulinum toxin type “A” administration for management of urinary incontinence secondary to neuropathic detrusor overactivity in children: long-term follow-up. Urology. 2018;114:167–74.CrossRefPubMed Ladi-Seyedian SS, Sharifi-Rad L, Kajbafzadeh AM. Intravesical electromotive botulinum toxin type “A” administration for management of urinary incontinence secondary to neuropathic detrusor overactivity in children: long-term follow-up. Urology. 2018;114:167–74.CrossRefPubMed
68.••
go back to reference Koschorke M, Leitner L, Sadri H, Knüpfer SC, Mehnert U, Kessler TM. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment? BJU Int. 2017; 120: 848–54. This study recommend urodynamic investigations as a routine part of the follow-up in patients after BTX injestions. Koschorke M, Leitner L, Sadri H, Knüpfer SC, Mehnert U, Kessler TM. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment? BJU Int. 2017; 120: 848–54. This study recommend urodynamic investigations as a routine part of the follow-up in patients after BTX injestions.
69.
go back to reference Neel KF, Soliman S, Salem M, Seida M, Al-Hazmi H, Khatab A. Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder. J Urol. 2007;178:2593–7. discussion 2597-8.CrossRefPubMed Neel KF, Soliman S, Salem M, Seida M, Al-Hazmi H, Khatab A. Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder. J Urol. 2007;178:2593–7. discussion 2597-8.CrossRefPubMed
70.
go back to reference Tsai SJ, Ying TH, Huang YH, Cheng JW, Bih LI, Lew HL. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil. 2009;90:832–6.CrossRefPubMed Tsai SJ, Ying TH, Huang YH, Cheng JW, Bih LI, Lew HL. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil. 2009;90:832–6.CrossRefPubMed
71.
go back to reference Mokhless I, Zahran AR, Saad A, Yehia M, Youssif ME. Effect of botox injection at the bladder neck in boys with bladder dysfunction after valve ablation. J Pediatr Urol. 2014;10:899–904.CrossRefPubMed Mokhless I, Zahran AR, Saad A, Yehia M, Youssif ME. Effect of botox injection at the bladder neck in boys with bladder dysfunction after valve ablation. J Pediatr Urol. 2014;10:899–904.CrossRefPubMed
72.
go back to reference Sager C, Burek C, Bortagaray J, Corbetta JP, Weller S, Durán V, et al. Repeated injections of intradetrusor onabotulinumtoxinA as adjunctive treatment of children with neurogenic bladder. Pediatr Surg Int. 2014;30:79–85.CrossRefPubMed Sager C, Burek C, Bortagaray J, Corbetta JP, Weller S, Durán V, et al. Repeated injections of intradetrusor onabotulinumtoxinA as adjunctive treatment of children with neurogenic bladder. Pediatr Surg Int. 2014;30:79–85.CrossRefPubMed
73.
go back to reference Horst M, Weber DM, Bodmer C, Gobet R. Repeated botulinum-a toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele. Neurourol Urodyn. 2011;30:1546–9.CrossRefPubMed Horst M, Weber DM, Bodmer C, Gobet R. Repeated botulinum-a toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele. Neurourol Urodyn. 2011;30:1546–9.CrossRefPubMed
74.
go back to reference Tiryaki S, Yagmur I, Parlar Y, Ozel K, Akyildiz C, Avanoglu A, et al. Botulinum injection is useless on fibrotic neuropathic bladders. J Pediatr Urol. 2015;11:27.e1–4.CrossRef Tiryaki S, Yagmur I, Parlar Y, Ozel K, Akyildiz C, Avanoglu A, et al. Botulinum injection is useless on fibrotic neuropathic bladders. J Pediatr Urol. 2015;11:27.e1–4.CrossRef
75.
go back to reference Kim SW, Choi JH, Lee YS, Han SW, Im YJ. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity. Urology. 2014;84:1480–4.CrossRefPubMed Kim SW, Choi JH, Lee YS, Han SW, Im YJ. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity. Urology. 2014;84:1480–4.CrossRefPubMed
76.
go back to reference Kajbafzadeh AM, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH, et al. Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology. 2006;68:1091–6. discussion 1096-7. Kajbafzadeh AM, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH, et al. Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology. 2006;68:1091–6. discussion 1096-7.
77.
go back to reference Figueroa V, Romao R, Pippi Salle JL, Koyle MA, Braga LH, Bägli DJ, et al. Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures. J Pediatr Urol. 2014;10:368–73.CrossRefPubMed Figueroa V, Romao R, Pippi Salle JL, Koyle MA, Braga LH, Bägli DJ, et al. Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures. J Pediatr Urol. 2014;10:368–73.CrossRefPubMed
78.
go back to reference Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type a in children with neurogenic bladder due to myelomeningocele. J Urol. 2006;175:1102–5.CrossRefPubMed Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type a in children with neurogenic bladder due to myelomeningocele. J Urol. 2006;175:1102–5.CrossRefPubMed
79.
go back to reference Blackburn SC, Jones C, Bedoya S, Steinbrecher HA, Malone PS, Griffin SJ. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children. J Pediatr Urol. 2013;9:750–3.CrossRefPubMed Blackburn SC, Jones C, Bedoya S, Steinbrecher HA, Malone PS, Griffin SJ. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children. J Pediatr Urol. 2013;9:750–3.CrossRefPubMed
80.
go back to reference Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30:556–62.CrossRefPubMed Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30:556–62.CrossRefPubMed
81.
go back to reference Greer T, Abbott J, Breytenbach W, McGuane D, Barker A, Khosa J, et al. Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. J Pediatr Urol. 2016;12:94.e1–6.CrossRef Greer T, Abbott J, Breytenbach W, McGuane D, Barker A, Khosa J, et al. Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. J Pediatr Urol. 2016;12:94.e1–6.CrossRef
82.•
go back to reference Neel KF, Salem M, Soliman S. Total endoscopic management (TEM approach) of children with non-compliant neuropathic bladder: a preliminary report. J Pediatr Urol. 2008;4:124–6. This trial confirmed that combination of endoscopic BTX injection with correction of vesico-ureteric reflux is a simple and effective way manage children with NB. Neel KF, Salem M, Soliman S. Total endoscopic management (TEM approach) of children with non-compliant neuropathic bladder: a preliminary report. J Pediatr Urol. 2008;4:124–6. This trial confirmed that combination of endoscopic BTX injection with correction of vesico-ureteric reflux is a simple and effective way manage children with NB.
83.••
go back to reference Shepherd JP, Carter-Brooks CM, Chermanksy C. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactivebladder. Int Urogynecol J. 2018;29:1213–9. This study showed that BTX injestion is a cost-effective therapy for overactive bladder. Shepherd JP, Carter-Brooks CM, Chermanksy C. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactivebladder. Int Urogynecol J. 2018;29:1213–9. This study showed that BTX injestion is a cost-effective therapy for overactive bladder.
84.
go back to reference Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014;84:1044–8.CrossRefPubMed Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014;84:1044–8.CrossRefPubMed
85.
go back to reference Patel DN, Jamnagerwalla J, Houman J, Anger JT, Eilber KS. What is the true catheterization rate after intravesical onabotulinumtoxinA injection? Int Urogynecol J. 2018;29:1005–9.CrossRefPubMed Patel DN, Jamnagerwalla J, Houman J, Anger JT, Eilber KS. What is the true catheterization rate after intravesical onabotulinumtoxinA injection? Int Urogynecol J. 2018;29:1005–9.CrossRefPubMed
86.
go back to reference Bayrak O, Sadioglu E, Sen H, Dogan K, Erturhan S, Seckiner I. Efficacy of onabotulinum toxin A injection in pediatric patients with non-neurogenic detrusor overactivity. Neurourol Urodyn. 2017;36:2078–82.CrossRefPubMed Bayrak O, Sadioglu E, Sen H, Dogan K, Erturhan S, Seckiner I. Efficacy of onabotulinum toxin A injection in pediatric patients with non-neurogenic detrusor overactivity. Neurourol Urodyn. 2017;36:2078–82.CrossRefPubMed
87.
go back to reference Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32:1109–15.CrossRefPubMed Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32:1109–15.CrossRefPubMed
Metadata
Title
The Current Role of Botox in a Pediatric Neurogenic Bladder Condition
Author
Paweł Kroll
Publication date
01-06-2019
Publisher
Springer US
Published in
Current Bladder Dysfunction Reports / Issue 2/2019
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-019-00516-9

Other articles of this Issue 2/2019

Current Bladder Dysfunction Reports 2/2019 Go to the issue

Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Urinary Biomarkers and Benign Prostatic Hyperplasia

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

The Inflammatory Contracted Bladder

Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

The Effect of Major Pelvic Extirpative Surgery on Lower Urinary Tract Function

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Urethral Pain Syndrome: A Systematic Review

Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Molecular Characteristics of Underactive Bladder

BPH-Related Voiding Dysfunction (R Lee, Section Editor)

The WATER Study: a Review